In recent years, global collaboration has become a commonly used strategy for new drug development. To accelerate the development process and shorten the approval time, the design of multi-regional clinical trials (MRCTs) incorporates subjects from many countries around the world under the same protocol. After showing the overall efficacy of a drug in all global regions, one can also simultaneously evaluate the possibility of applying the overall trial results to all regions and subsequently support drug registration in each of them. Several statistical methods have been proposed for the design and evaluation of MRCTs. Most of these approaches, however, assume a common variability of the primary endpoint across regions. In practice, this assumption may not be true due to differences across regions. In this paper, we use a random effect model for modeling heterogeneous variability across regions for the design and evaluation of MRCTs.
Date:
2013-09
Relation:
Topics in Applied Statistics. 2013 Sep;55:325-344.
